Voxzogo-Becomes-First-in-Class-Treatment-for-Dwarfism
Voxzogo Becomes First-in-Class Treatment for Dwarfism
November 19, 2021
First Generic for Somatuline Depot Approved
December 17, 2021
Voxzogo-Becomes-First-in-Class-Treatment-for-Dwarfism
Voxzogo Becomes First-in-Class Treatment for Dwarfism
November 19, 2021
First Generic for Somatuline Depot Approved
December 17, 2021
COVID-19-Booster-Shots-Authorized-for-All-Adults

November 19, 2021 – The U.S. FDA has expanded emergency use authorization (EUA) for the Pfizer/BioNTech and Moderna COVID-19 vaccines. They can now be used to administer a booster dose to all U.S. adults who have completed primary vaccination with any FDA-authorized or approved COVID-19 vaccine.

  • Adults who received the Pfizer/BioNTech or Moderna vaccine for primary vaccination can receive a booster dose of either product at least six months after completing primary vaccination.
  • Adults who received the Janssen (Johnson & Johnson) vaccine for primary vaccination can receive a Pfizer/BioNTech or Moderna booster at least two months after receiving the Janssen vaccine.
  • Under the EUA, individuals do not have to receive the same brand of vaccine for their booster dose as they received for their primary vaccination series.